Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Molecular Medicine for Neurodegenerative and Neuromuscular Diseases Unit, |
RCV001346480 | SCV001519091 | likely pathogenic | Adrenoleukodystrophy | 2021-01-04 | criteria provided, single submitter | research | |
Labcorp Genetics |
RCV001346480 | SCV001540688 | likely benign | Adrenoleukodystrophy | 2024-01-11 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001346480 | SCV002045780 | uncertain significance | Adrenoleukodystrophy | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001346480 | SCV002084663 | uncertain significance | Adrenoleukodystrophy | 2020-05-10 | no assertion criteria provided | clinical testing | |
Prevention |
RCV003953665 | SCV004767208 | likely benign | ABCD1-related disorder | 2023-12-06 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |